Compromises Set To Unlock TPP Endgame?
This article was originally published in PharmAsia News
What is expected to be the final round of ministerial talks to seal the long-planned Trans-Pacific Partnership free trade agreement has begun in Atlanta, but external opposition to expected drug and particularly biologics intellectual property measures remains firm.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.